Cabaletta Bio, Inc. (CABA)
Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.
Address
2929 ARCH STREET
PHILADELPHIA, PA 19104
Founded
2017
Number of Employees
103
Website
http://www.cabalettabio.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)